Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-015540
Filing Date
2022-08-08
Accepted
2022-08-08 16:17:21
Documents
65
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cyt-20220630.htm   iXBRL 10-Q 2016689
2 EX-31.1 cyt-ex31_1.htm EX-31.1 20257
3 EX-31.2 cyt-ex31_2.htm EX-31.2 20233
4 EX-32.1 cyt-ex32_1.htm EX-32.1 11785
5 EX-32.2 cyt-ex32_2.htm EX-32.2 11771
  Complete submission text file 0000950170-22-015540.txt   6468862

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20220630_lab.xml EX-101.LAB 358066
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cyt-20220630_cal.xml EX-101.CAL 41281
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cyt-20220630_def.xml EX-101.DEF 132364
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20220630.xsd EX-101.SCH 41623
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20220630_pre.xml EX-101.PRE 256285
59 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20220630_htm.xml XML 1049467
Mailing Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421
Business Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

EIN.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40499 | Film No.: 221144621
SIC: 2834 Pharmaceutical Preparations